Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study

Daratumumab, lenalidomide, dexamethasone (DRd) and bortezomib, lenalidomide, dexamethasone (VRd) are the preferred first-line regimens for transplant-ineligible newly diagnosed multiple myeloma, but there is no head-to-head study comparing these regimens. This multicenter chart review compared the progression-free survival of DRd versus VRd as first-line therapy. DRd was associated with a significantly lower risk of disease progression or death compared to VRd.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 13, 2023 Category: Hematology Authors: Lucio Navarro Gordan, Carlyn Rose Tan, Robert Vescio, Jing Christine Ye, Carolina Schinke, Rohan Medhekar, Alex Z. Fu, Marie-H élène Lafeuille, Philippe Thompson-Leduc, Vipin Khare, John Reitan, Gary Milkovich, Shuchita Kaila, Faith Davies, Saad Z. Usma Tags: Original Study Source Type: research